How do you respond to an FDA Form 483, and how many days do you have?

1What a Form 483 is, and why the response matters.

FDA issues a Form 483 to company management at the end of an inspection when an investigator has observed conditions that, in their judgement, may constitute violations of the Federal Food, Drug, and Cosmetic Act. It is not a final agency determination. FDA considers it together with the Establishment Inspection Report, the evidence collected and any response from the company before deciding what further action, if any, is appropriate.¹ Nor is it a complete list: companies are responsible for correcting the cited conditions “and any related non-cited objectionable conditions that might exist”.¹

For drug manufacturers, FDA’s March 2026 draft guidance says a written response “may be the primary or a key component” in FDA’s review of whether further action is warranted, and recommends that establishments take this voluntary opportunity.² Finished-drug manufacturers must already have procedures to make sure responsible officials who were not personally involved or immediately aware are notified in writing of reports of inspectional observations issued by FDA, under 21 CFR 211.180(f).³

2How many days you have.

The 15 business days come from a programme FDA announced in August 2009 to support the timely issuance of warning letters. Before issuing one, FDA generally allows a firm 15 business days to respond to a 483 and reviews a timely response in detail; it “will not ordinarily delay the issuance of a warning letter” to review a response received later.⁴ The March 2026 draft guidance keeps that position for drug CGMP inspections.²

FDA can issue a warning letter at any time, and partially implemented or promised corrective actions do not preclude regulatory action.⁴²

3What the response should contain.

The draft guidance asks for a table of contents and at least these elements:²

1. The establishment’s name, the full address of the inspected site and its FDA Establishment Identifier (FEI), which is at the top of the 483.
2. A copy of the 483.
3. Who prepared the response and, if it was not the establishment, their relationship to it, such as consultant, US agent or outside counsel.
4. Who signed it. FDA asks for a signature from executive management “who allocates resources and has the authority to implement commitments”; a site head or head of the quality unit may also sign.
5. Letters of authorisation for any consultant or outside counsel.
6. Any global investigation plans and reports.
7. An executive summary of all remediation, then for each observation or group of observations: a patient- and product-focused risk assessment that covers inventory and distributed drugs still within expiry; an investigation report with scope, affected drugs and lot numbers, root causes, any systemic issues, the CAPA plan, completed and interim actions and the planned effectiveness evaluation; and signed attachments.
8. A discussion of each observation in its own numbered section. Observations may be grouped by topic.

FDA suggests summarising the remediation in a table that gives, for each observation, its category or system, a summary of the issue and CAPA, the CAPA number, the target date and current progress. Correspondence should be in English. A translation should come with the original document and a statement of the translator’s qualifications, and FDA generally does not intend to review foreign-language documents sent without one. Responses go to the email address on the 483, with files over 100 megabytes split or sent through another electronic gateway.²

4How to work through the observations.

Start with risk to patients and product. Management should fully understand every observation and assess the risks during and immediately after the inspection. Actions may include notifying customers, recalling drugs, additional testing, adding lots to stability programmes, or amending or supplementing applications.² A 483 response does not replace a Field Alert Report or Biological Product Deviation Report where one is required.²

Then set the investigation’s scope. FDA expects establishments to prioritise by severity, to cluster observations by category or by system (quality, production, facilities and equipment, packaging and labelling, materials, laboratory control), to check past inspections and internal audits for repeat observations, and to extend the investigation to other drugs, processes, facilities and contract organisations the deficiency could affect.² Its example is a cleaning observation on one piece of equipment: once interviews show the same procedure is used elsewhere, the investigation should cover all that equipment, every drug made on it and the adequacy of all the cleaning procedures. This follows 21 CFR 211.192, which requires an unexplained discrepancy or failure to be thoroughly investigated, extended to other batches and products that may be associated with it, and recorded with its conclusions and follow-up.⁵

The guidance warns that “addressing the most obvious causal factor is often not sufficient”, and that testing only the first hypothesis can bias the result. It suggests asking why the quality unit or management did not find the issue before the inspection, and recommends a CGMP consultant when observations involve data integrity. CAPA plans and commitments should be “realistic, measurable, and achievable”, and an effectiveness check “should consist of more than routine sampling and testing”. FDA may check both at the next inspection.²

5Interim reports, disagreements and what happens next.

For work that is not complete, send preliminary results with a timeline and the interim measures in place, and set out a communication plan with milestones and the dates of follow-up reports.² If you disagree with an observation on scientific or technical grounds, describe the contested facts in the response with supporting data and the statutes, regulations or guidance you rely on. The FDA Ombudsman is also available.²

After the inspection FDA reviews the findings, the evidence and the response, and may concur with, downgrade or upgrade the final CGMP classification.⁶ For human drug facilities, FDA aims to classify the inspection within 90 days and writes to the facility with the result.⁷ See what NAI, VAI and OAI mean.

The draft guidance covers manufacturers whose drugs are regulated by CDER, CBER and CVM, including 503B outsourcing facilities and combination products where CDER or CBER leads. Device establishments have a separate CDRH guidance on nonbinding feedback after certain device inspections, from April 2020.² The March 2026 document is a draft: “Not for implementation. Contains non-binding recommendations.”²

6How it runs in Seal.

In Seal’s inspection readiness workflow, an observation, such as a Form 483 item, becomes a tracked commitment. The finding, cited requirement, response, interim controls, CAPA, owners and verification stay connected, and an action is not treated as closed because a response letter was sent. A response commitment keeps its interim control, CAPA linkage, submission package, authority acknowledgement and verification.

Each CAPA keeps its source, investigation, actions, effectiveness review and closure in one record, and closure can be configured to require the approved effectiveness review. Neil can assemble the evidence behind a specific question and make missing evidence explicit. Your audit owner checks scope and completeness before anything is shared, and Neil does not send records to the auditor.